{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:43:42Z","timestamp":1790109822750,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.modpat.2023.100299","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T11:34:23Z","timestamp":1691408063000},"page":"100299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Sherry","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Da Cruz Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iaosonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Tessier-Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Troso-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora H.","family":"Ellenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-3996","authenticated-orcid":false,"given":"M. Herman","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.modpat.2023.100299_bib1","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.modpat.2023.100299_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100299_bib3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100299_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.modpat.2023.100299_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"issue":"15","key":"10.1016\/j.modpat.2023.100299_bib6","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.modpat.2023.100299_bib7","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.modpat.2023.100299_bib8","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2023.100299_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.gore.2016.12.003","article-title":"Regression of metastatic, radiation\/chemotherapy-resistant uterine serous carcinoma overexpressing HER2\/neu with trastuzumab emtansine (TDM-1)","volume":"19","author":"Santin","year":"2017","journal-title":"Gynecol Oncol Rep"},{"issue":"11","key":"10.1016\/j.modpat.2023.100299_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.modpat.2023.100299_bib12","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to trastuzumab in breast cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.modpat.2023.100299_bib13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/annonc\/mdw197","article-title":"PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab","volume":"27","author":"Loibl","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100299_bib14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2015.306","article-title":"PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2\/neu overexpressing uterine serous carcinomas","volume":"113","author":"Black","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2023.100299_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13059-015-0657-6","article-title":"Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification","volume":"16","author":"Ng","year":"2015","journal-title":"Genome Biol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100299_bib16","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.modpat.2023.100299_bib17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100299_bib18","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ejca.2012.10.018","article-title":"Clinical significance of intratumoral HER2 heterogeneity in gastric cancer","volume":"49","author":"Lee","year":"2013","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.modpat.2023.100299_bib19","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","article-title":"HER2 heterogeneity in gastric\/gastroesophageal cancers: from benchside to practice","volume":"22","author":"Grillo","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100299_bib20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.modpat.2023.100299_bib21","series-title":"WHO Classification of Tumours 5th Edition\u2014Female Genital Tumours","year":"2020"},{"issue":"2","key":"10.1016\/j.modpat.2023.100299_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2023.100299_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 Testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.modpat.2023.100299_bib25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100299_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.modpat.2023.100299_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5858\/133.4.611","article-title":"Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines","volume":"133","author":"Vance","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.modpat.2023.100299_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering\u2013integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"issue":"2","key":"10.1016\/j.modpat.2023.100299_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.modpat.2023.100299_bib30","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1038\/s41467-021-27093-y","article-title":"HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.modpat.2023.100299_bib31","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1073\/pnas.1014835108","article-title":"Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients","volume":"108","author":"Scaltriti","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.modpat.2023.100299_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100299_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1309\/AJCPXTZSKBRIP07W","article-title":"Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity","volume":"136","author":"Allison","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100299_bib34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.modpat.2023.100299_bib35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/PAI.0000000000000136","article-title":"HER2 genetic heterogeneity in gastric cancer: evaluation according to the College of American Pathologists Breast Cancer Criteria","volume":"23","author":"Treacy","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100299_bib36","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","article-title":"Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer","volume":"53","author":"Wakatsuki","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100299_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2023.100299_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100299_bib39","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-20-4436","article-title":"Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas","volume":"27","author":"Momeni-Boroujeni","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223002041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223002041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:25:01Z","timestamp":1760232301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223002041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0893395223002041"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100299","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100299"}}